VRDN
Viridian TherapeuticsBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-03
Current thesis
Successful pivotal/late‑stage readouts and constructive reimbursement progress lift sentiment to the high analyst estimates; commercial uptake and limited dilution sustain a path to the high‑end target.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta 0.0.
What can break
Commercial or reimbursement failure
Momentum
28
Value
41
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $41.71 · Bull $61.00 · Bear $26.00
Data freshness
Prices
As of 2026-06-03
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-03 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-15 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-03
Investment thesis
As of 2026-06-03
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $41.50
Why
Momentum28 · Δ7d +16.9
Value41 · Δ7d +0.0
Sentiment100 · Δ7d 0.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
28
34% active weight
Current posture
7d trendImproving
Δ7d
+16.9
Δ21d
+26.9
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
+0.2
Sentiment
100
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade B. Momentum 27.9 / Value 41.1 / Sentiment 100.0
Fundamentals (TTM)As of 2026-06-02
Fundamentals (TTM)
As of 2026-06-02
Market Cap
$1.75B
Beta
0.96
Shares Out
95.44M
P/E (TTM) · Derived
-5.5
P/S (TTM)
40.72
P/FCF (TTM) · Derived
-4.57
Rev YoY
+81958.1%
EPS YoY
+63.4%
Gross Margin
-
Op Margin
-463.5%
Net Debt
-$697M
Current Ratio
11.28
As of 2026-06-03 • Updated nightlySource: Internal modelMethodology